Indaptus Therapeutics Inc INDP 深 沪
等待开盘 12-18 09:30:00 美东时间
2.16
-0.050
-2.26%
华盛通- 最 高2.23
- 今 开2.19
- 成交量 1.86万股
- 最 低 2.09
- 昨 收 2.21
- 总市值 239.00万
- 52周最高 47.60
- 市盈率 静 --
- 换手率 1.68%
- 52周最低 1.65
- 委 比 -88.89%
- 总股本 110.65万
- 历史最高 21952.00
- 量 比 2.08
- 振 幅 6.33%
- 历史最低 2.09
- 每 手 1
- 风险率 8.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Indaptus Therapeutics Q3 EPS $(2.98) Beats $(4.17) Estimate
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(2.98) per share which beat the analyst consensus estimate of $(4.17) by 28.54 percent. This is a 67.04 percent increase over losses of $(9.04) per share
11-12 21:35
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket
Shares of CSX Corp (NASDAQ:CSX) rose sharply in pre-market trading after the co...
10-17 17:55
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
09-27 01:05
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...
09-05 05:13
Indaptus Reports Partial Response From Decoy20 Monotherapy In Urothelial Cancer; Combo With PD-1 Inhibitor Shows Favorable Safety
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastasesDecoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agentNEW YORK,
09-05 04:02
Indaptus Therapeutics Provides Clinical Update
Indaptus Therapeutics announced updates on their INDP-D101 clinical trial for Decoy20, a potential cancer treatment. In monotherapy, a patient with urothelial cancer and liver metastases experienced partial response, though disease progression led to discontinuation. In combination with PD-1 inhibitor tislelizumab, safety profiles align with each agent. Initial data on 7 patients in the combination cohort show varied outcomes. Financially, the co...
09-04 20:01
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
Indaptus Therapeutics CEO Jeffrey Meckler will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:30 PM ET in Kennedy I (4th Floor), Lotte New York Palace Hotel. A live webcast will be available on the company's investor relations website, with a replay archived for 90 days. Meckler will discuss the company's innovative immunotherapy platform, which uses a multi-targeted approach to activate immune ...
09-02 20:05
Indaptus Therapeutics Q2 EPS $(9.09) Beats $(9.24) Estimate
Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(9.09) per share which beat the analyst consensus estimate of $(9.24) by 1.62 percent. This is a 30.93 percent increase over losses of $(13.16) per share
08-13 20:11
Indaptus Therapeutics Secures Approval for Private Placement
Indaptus Therapeutics ( ($INDP) ) just unveiled an announcement. Indaptus Thera...
07-30 04:58
